CY1124140T1 - Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης - Google Patents
Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασηςInfo
- Publication number
- CY1124140T1 CY1124140T1 CY20211100256T CY211100256T CY1124140T1 CY 1124140 T1 CY1124140 T1 CY 1124140T1 CY 20211100256 T CY20211100256 T CY 20211100256T CY 211100256 T CY211100256 T CY 211100256T CY 1124140 T1 CY1124140 T1 CY 1124140T1
- Authority
- CY
- Cyprus
- Prior art keywords
- therapeutic treatment
- cell disorders
- hyperplastic cell
- entities
- telomerase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
- G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
Abstract
Παρέχονται στο παρόν μέθοδοι για τον προσδιορισμό οντοτήτων διαγνωσμένων με μία υπερπλαστική διαταραχή των κυττάρων που θα ωφεληθούν από την θεραπευτική αγωγή με ένωση αναστολέα τελομεράσης. Παρέχονται επίσης στο παρόν μέθοδοι για την θεραπευτική αντιμετώπιση σε τέτοιες οντότητες με ενώσεις αναστολέα τελομεράσης. Οι μέθοδοι περιέχουν τον προσδιορισμό οντοτήτων που θα ωφεληθούν από την εν λόγω θεραπευτική αγωγή που βασίζεται στο μέσο σχετικό μήκος των τελομερών σε καρκινικά κύτταρα από τις εν λόγω οντότητες.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261732263P | 2012-11-30 | 2012-11-30 | |
US201361780851P | 2013-03-13 | 2013-03-13 | |
US13/802,035 US9200327B2 (en) | 2012-11-30 | 2013-03-13 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
US201361798478P | 2013-03-15 | 2013-03-15 | |
US201361809228P | 2013-04-05 | 2013-04-05 | |
EP13858528.6A EP2925889B1 (en) | 2012-11-30 | 2013-11-27 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
PCT/US2013/072302 WO2014085632A1 (en) | 2012-11-30 | 2013-11-27 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124140T1 true CY1124140T1 (el) | 2022-05-27 |
Family
ID=50828470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100256T CY1124140T1 (el) | 2012-11-30 | 2021-03-23 | Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης |
Country Status (24)
Country | Link |
---|---|
EP (3) | EP3882355B1 (el) |
JP (2) | JP6359028B2 (el) |
KR (3) | KR102174763B1 (el) |
CN (2) | CN111494629A (el) |
AU (3) | AU2013352105B2 (el) |
BR (1) | BR112015012507B1 (el) |
CA (1) | CA2892445C (el) |
CY (1) | CY1124140T1 (el) |
DK (2) | DK2925889T3 (el) |
ES (3) | ES2865446T3 (el) |
HK (1) | HK1215874A1 (el) |
HR (2) | HRP20181991T1 (el) |
HU (1) | HUE054053T2 (el) |
IL (3) | IL282112B (el) |
LT (2) | LT2925889T (el) |
MX (1) | MX362094B (el) |
NZ (2) | NZ748624A (el) |
PL (2) | PL2925889T3 (el) |
PT (2) | PT3495495T (el) |
RS (1) | RS61513B1 (el) |
SG (1) | SG11201504209YA (el) |
SI (2) | SI3495495T1 (el) |
WO (1) | WO2014085632A1 (el) |
ZA (2) | ZA201900759B (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2342360B1 (en) | 2008-10-17 | 2016-01-06 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
WO2018207952A1 (ja) * | 2017-05-12 | 2018-11-15 | 国立大学法人九州大学 | 発毛及び/又は育毛用組成物 |
MX2021001255A (es) * | 2018-07-31 | 2021-04-12 | Geron Corp | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa. |
GB201818792D0 (en) * | 2018-11-19 | 2019-01-02 | Telonostix Ltd | Compounds for telomere length-related treatment of cancer |
EP3674418A1 (en) * | 2018-12-26 | 2020-07-01 | Life Length S.L. | Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases |
CN114306602B (zh) * | 2020-09-28 | 2024-06-11 | 中国科学院上海营养与健康研究所 | 靶向tert在调节皮肤及毛发色素中的应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
CA2274586A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
JPH11276182A (ja) * | 1997-12-26 | 1999-10-12 | Chugai Pharmaceut Co Ltd | 逆転写酵素モチーフを有する新規遺伝子 |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
ATE534746T1 (de) | 2002-01-31 | 2011-12-15 | Univ Utah | Amplifizieren repetitiver nukleinsäuresequenzen |
US20040234961A1 (en) * | 2002-04-22 | 2004-11-25 | Fordyce Colleen A. | Telomere length determination and applications |
EP1585974B1 (en) | 2003-01-24 | 2013-02-27 | University of Utah | Methods of predicting mortality risk by determining telomere length |
EP1667522B1 (en) | 2003-09-09 | 2018-01-17 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
LT3296312T (lt) | 2004-07-02 | 2021-06-10 | Geron Corporation | Apsaugotų 3'-amino-5'-fosforamidito nukleozido monomerų sintezė |
CN101193643A (zh) * | 2005-03-25 | 2008-06-04 | Alt解决方案公司 | 端粒酶阳性细胞中端粒长度的调节和癌症治疗 |
WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
EP2342360B1 (en) * | 2008-10-17 | 2016-01-06 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
CN107083444B (zh) | 2008-12-22 | 2023-03-14 | 犹他大学研究基金会 | 单色多重定量pcr |
US20110207128A1 (en) | 2010-02-16 | 2011-08-25 | Cawthon Richard M | Methods and kits for determining biological age and longevity based on gene expression profiles |
JP6273198B2 (ja) * | 2011-03-28 | 2018-01-31 | ジェロン・コーポレーションGeron Corporation | 定量的pcrによる、ホルマリン固定パラフィン包埋(ffpe)試料におけるテロメア長測定 |
-
2013
- 2013-11-27 KR KR1020157017235A patent/KR102174763B1/ko active IP Right Grant
- 2013-11-27 KR KR1020217027659A patent/KR20210112394A/ko not_active Application Discontinuation
- 2013-11-27 HU HUE18192236A patent/HUE054053T2/hu unknown
- 2013-11-27 ES ES18192236T patent/ES2865446T3/es active Active
- 2013-11-27 NZ NZ748624A patent/NZ748624A/en unknown
- 2013-11-27 PL PL13858528T patent/PL2925889T3/pl unknown
- 2013-11-27 EP EP20214086.9A patent/EP3882355B1/en active Active
- 2013-11-27 BR BR112015012507-7A patent/BR112015012507B1/pt active IP Right Grant
- 2013-11-27 SG SG11201504209YA patent/SG11201504209YA/en unknown
- 2013-11-27 EP EP18192236.0A patent/EP3495495B1/en active Active
- 2013-11-27 RS RS20210254A patent/RS61513B1/sr unknown
- 2013-11-27 WO PCT/US2013/072302 patent/WO2014085632A1/en active Application Filing
- 2013-11-27 CN CN201911349502.4A patent/CN111494629A/zh active Pending
- 2013-11-27 SI SI201331864T patent/SI3495495T1/sl unknown
- 2013-11-27 KR KR1020207031441A patent/KR102348240B1/ko active IP Right Grant
- 2013-11-27 DK DK13858528.6T patent/DK2925889T3/da active
- 2013-11-27 DK DK18192236.0T patent/DK3495495T3/da active
- 2013-11-27 EP EP13858528.6A patent/EP2925889B1/en active Active
- 2013-11-27 PT PT181922360T patent/PT3495495T/pt unknown
- 2013-11-27 JP JP2015545446A patent/JP6359028B2/ja active Active
- 2013-11-27 AU AU2013352105A patent/AU2013352105B2/en active Active
- 2013-11-27 ES ES20214086T patent/ES2972330T3/es active Active
- 2013-11-27 LT LTEP13858528.6T patent/LT2925889T/lt unknown
- 2013-11-27 SI SI201331271T patent/SI2925889T1/sl unknown
- 2013-11-27 ES ES13858528T patent/ES2703914T3/es active Active
- 2013-11-27 PT PT13858528T patent/PT2925889T/pt unknown
- 2013-11-27 MX MX2015006538A patent/MX362094B/es active IP Right Grant
- 2013-11-27 NZ NZ708654A patent/NZ708654A/en unknown
- 2013-11-27 PL PL18192236T patent/PL3495495T3/pl unknown
- 2013-11-27 LT LTEP18192236.0T patent/LT3495495T/lt unknown
- 2013-11-27 IL IL282112A patent/IL282112B/en unknown
- 2013-11-27 CA CA2892445A patent/CA2892445C/en active Active
- 2013-11-27 CN CN201380070816.5A patent/CN104937110A/zh active Pending
-
2015
- 2015-05-27 IL IL239035A patent/IL239035B/en active IP Right Grant
-
2016
- 2016-04-01 HK HK16103783.7A patent/HK1215874A1/zh unknown
-
2018
- 2018-02-13 JP JP2018022923A patent/JP2018099127A/ja active Pending
- 2018-11-27 HR HRP20181991TT patent/HRP20181991T1/hr unknown
-
2019
- 2019-02-06 ZA ZA2019/00759A patent/ZA201900759B/en unknown
- 2019-11-13 IL IL270636A patent/IL270636B/en active IP Right Grant
- 2019-12-18 AU AU2019283840A patent/AU2019283840A1/en not_active Abandoned
-
2021
- 2021-02-26 ZA ZA2021/01317A patent/ZA202101317B/en unknown
- 2021-03-17 HR HRP20210451TT patent/HRP20210451T1/hr unknown
- 2021-03-23 CY CY20211100256T patent/CY1124140T1/el unknown
-
2022
- 2022-04-28 AU AU2022202808A patent/AU2022202808A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124140T1 (el) | Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης | |
CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
CY1123957T1 (el) | Θεραπεια συνδυασμου για καρκινο | |
CY1123776T1 (el) | Μεθοδοι για την αντιμετωπιση καταστασεων που συνδεονται με την ενεργοποιηση συμπληρωματος εξαρτωμενου απο την μasp-2 | |
CY1124617T1 (el) | Ενωσεις βενζολιου υποκατεστημενες με αρυλιο ή ετεροαρυλιο | |
CY1121390T1 (el) | Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων | |
CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
CY1120581T1 (el) | Ενωσεις και μεθοδοι χρησης τους | |
CY1120374T1 (el) | Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια | |
CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
CY1118933T1 (el) | Anti-cxcr1 συνθεσεις και μεθοδοι | |
NI201400078A (es) | Derivados de lactamas útiles como inhibidores mutantes de idh1 | |
UY34736A (es) | ?compuestos de indol e indazol que activan la ampk?. | |
CL2013000935A1 (es) | Compuestos derivados de bencimidazol o sus sales, como inhibidores de cinasa pi3; composicion farmaceutica que los comprende; y su uso para el tratamiento de un neoplasma deficiente en pten seleccionado entre gliomas de cerebro, cancer de mama, cancer de prostata, cancer gastrico y mieloma multiple, entre otros. | |
TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
MY170983A (en) | Biomarker assays for detecting or measuring inhibition of tor kinase activity | |
CY1117654T1 (el) | Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης | |
UY34654A (es) | Inhibidores de la beta-secretasa | |
EA201890598A3 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
TR201909951T4 (tr) | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. | |
MX2013007835A (es) | Combinacion de sirosingopina e inhibidores mitocondriales para el tratamiento de cancer e inmunosupresion. | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
MX348655B (es) | Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer. |